0.96 USD
▼+0.10-0.95%
盘后 0.97 -0.02%
2026-08-03
市值
$182.99M
市盈率
—
EPS
-0.49
股息率
—
52 周区间
0.86 – 1.63
成交量
1.36M
Beta
1.07
目标价
3.95
52W 低 0.8652W 高 1.63
价格走势
公司简介
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company’s flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in ...